Reda El badawy
Banha University, Egypt
Title: Study about 16sRNA Gene Gut Microbiome in HCV Patients Responders and Non Responders
Biography
Biography: Reda El badawy
Abstract
Background & Objectives: Still there is percentage of HCV patients not responding to Direct Antiviral Agents (DAAS), even the responder HCV patients needed to follow up. Gut flora (Microbiota) include all the microorganisms (its gene called 16sRNA microbiome). Liver can be greatly affected by changes in gut microbiome. This study was done to evaluate the association between gut flora and the response to DAAS in chronic HCV patients.
Methodology: Two groups, group 1(No=15 of HCV responders patients) and group 2(No=15 non responder HCV patients) treated by DAAS according to the treatment protocol of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH). Healthy control subjects (No=15) as third group age and sex matched compared to of HCV patients. All investigations were done plus stool culture & PCR for gene extraction by sequencing according to the manufacturer.
Results: The results show statistically significant difference between the patients (responders and non responders) and control, where p1 comparison between contro and responders, p2 between control and non responders, p3 between responders and non responders. Enterobacter organism in p2, p3 was <0.001&<0.005 respectively. Proteus and Clostridium perfringens in p2 was 0.009, 0.04 respectively .Klebsiella organism in p1, p2 was 0.04 and 0.01 respectively while Streptococci in p2 was 0,007.
Conclusion: Gut microbiome a have a crucial role in HCV patients specially the non responders compared to the control even the responders need to be followed up to adjust the gut flora of them to the normal because this proved to play an important role in micro environmental changes that lead to hepatocellular carcinoma(HCC).